Related Experiment Videos
Clinical trial evidence for cardiovascular risk reduction in type 2 diabetes
Irinel Stanciu1, Maylene L Peralta, Mary Ann Emanuele
1Department of Medicine, Loyola University Chicago, Maywood, Illinois, USA.
Abstract:
Major clinical trials have shown that excellent glycemic control, sustained over time, can prevent or delay the microvascular complications of diabetes, including retinopathy, nephropathy, and neuropathy. No prospective trial has clearly shown that glycemic intervention can prevent the macrovascular complications of diabetes, such as myocardial infarction, cerebrovascular accident, and amputation. However, a number of landmark clinical trials have shown the efficacy of control of blood pressure and lipids and use of antiplatelet agents (mainly aspirin) in protecting the macrovasculature of individuals with diabetes. In this article, glycemic, blood pressure, lipid, and antiplatelet trials relevant to the treatment of people with type 2 diabetes are reviewed.
Insights
Achieving excellent blood glucose control helps prevent diabetes-related microvascular complications. However, managing blood pressure, lipids, and using antiplatelet agents are key for preventing macrovascular complications in type 2 diabetes.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Glycemic control is proven to prevent microvascular complications in diabetes.
- Macrovascular complications of diabetes, like heart attack and stroke, have not been clearly prevented by glycemic intervention alone.
Purpose of the Study:
- To review clinical trials on glycemic, blood pressure, lipid, and antiplatelet interventions for type 2 diabetes management.
- To highlight strategies for preventing both microvascular and macrovascular complications.
Main Methods:
- Review of major clinical trials focusing on diabetes management.
- Analysis of data concerning glycemic control, blood pressure, lipid levels, and antiplatelet therapy.
Main Results:
- Sustained glycemic control effectively prevents or delays microvascular complications (retinopathy, nephropathy, neuropathy).
- Blood pressure control, lipid management, and antiplatelet agents (aspirin) are crucial for macrovascular protection in diabetes.
Conclusions:
- While glycemic control is vital for microvascular health, a multi-faceted approach is necessary for macrovascular protection in type 2 diabetes.
- Integrated management of glucose, blood pressure, lipids, and use of antiplatelet agents is recommended.